半侵入式脑机接口通过将电极放置在硬膜上或者硬膜下采集大脑中的神经信号，由于神经信号随着传输距离迅速衰减，半侵入式脑机接口所采集信号的 时间和空间分辨率较低，难以提取精细的神经编码信息；与之相比，侵入式脑机接口直接将柔性电极植入脑组织内部，从而能够精准捕获具有高时空间 分辨率的单神经元动作电位（Spikes）。因此， 侵入式脑机接口不仅能实现对精细动作的实时、高精度解码，更在人机交互的信息传输速率（Bit Rate）有数量级的优势。 在侵入式脑机接口技术的全球竞争中，国外市场由马斯克创办的Neuralink率先领跑，国内则由智冉医疗凭借在核心技术领域的突破，叠加全链条自主 创新优势，成为国产侵入式脑机接口的领军企业。 已完成侵入式脑机接口产业链上中游的系统化布局。 本文为IPO早知道原创 作者｜ 罗宾 微信公众号｜ipozaozhidao 据IPO早知道消息，近日，国内侵入式脑机接口企业「智冉医疗」宣布完成3亿元人民币A+轮融资。本轮融资由中科创星领投，老股东君联资本、北京 市医药健康产业投资基金、IDG资本、顺为资本、联想创投、元生创投、红杉中国、美团龙珠、BV百度风投、杏泽资本、佳银资本持续跟投。本轮所募 ...

近日，国内侵入式脑机接口领军企业智冉医疗完成3亿元A+轮融资，本轮融资由中科创星领投，老股东君联资本、北京市医药健康产业投资基金、IDG资 本、顺为资本、联想创投、元生创投、红杉中国、美团龙珠、BV百度风投、杏泽资本、佳银资本持续跟投，这也是智冉医疗在半年内完成的第二轮融资 据了解，本轮融资将主要用于推进大规模临床试验与高通量柔性脑机接口产品迭代，加速该技术向临床应用落地。 来源：猎云网 从创立之初，智冉就坚定地走侵入式脑机接口技术路线，一方面是因为团队在侵入式脑机接口底层技术拥有深厚的技术积累；另一方面，是基于对行业终局 的深刻认知。脑机接口的未来是要实现人类大脑与外部设备之间高带宽的信息交互，从而将脑机接口从一种'弥补缺陷'的辅助工具，进化为人类通往高效人 机共生的核心底层技术，而只有侵入式脑机接口的路线能够实现这一跨越。 当前，植入式脑机接口已然形成了两种技术路线：半侵入式脑机接口和侵入式脑机接口。两者的本质区别在于电极与脑组织的物理位置关系，这直接决定了 神经信号的质量与应用上限。半侵入式脑机接口通过将电极放置在硬膜上或者硬膜下采集大脑中的神经信号，由于神经信号随着传输距离迅速衰减，半侵入 式脑机接口 ...

本轮融资主要用于推进大规模临床试验、高通量柔性脑机接口产品迭代，加速侵入式脑机接口技术的临 床应用落地。 可拉伸柔性电极植入大脑后的动态运动效果，企业供图 除了攻克柔性电极的难点，成立至今，智冉医疗在神经芯片、解码算法与电极植入机器人方面，也已经 完成研发布局。另外，自建了近2000㎡临床级微纳加工车间与GMP标准组装车间，实现临床级产品的 全链条自主可控。 去年8月，智冉医疗刚获得超3亿元A轮融资。时隔半年再次拿到大额融资，且老股东集体加注，可见投 资机构对智冉医疗侵入式脑机接口全栈能力的认可。 智冉医疗创始人、CEO宋麒告诉36氪，从创立之初，智冉就坚定做侵入式脑机接口，一方面是因为团队 在侵入式脑机接口底层技术拥有深厚的技术积累；另一方面，脑机接口的未来终局不会限于瘫痪患者脑 控外设、功能重建等，而要实现高效的人机信息互通，只有侵入式脑机接口能够做到真正高通量、高质 量的信号读写。 "柔性电极"这一核心部件，可谓是侵入式脑机接口赛道的关键入场券。人的大脑是非常柔软的组织，电 极植入大脑皮层后，如何确保长期不移位，并减少因免疫反应产生瘢痕、而导致脑电信号衰减等，成为 重要研发方向。 智冉医疗创始人方英在柔 ...

Group 1 - The Federal Reserve Governor Waller stated that the current U.S. job market is "very weak" with near-zero growth, but there is no "cliff-like decline," indicating room for gradual interest rate cuts to reach neutral levels [1] - Oracle's data center project worth $10 billion faces funding challenges as Blue Owl Capital withdrew due to concerns over debt and AI spending, although Oracle confirmed that equity negotiations are proceeding as planned [1] - The U.S. stock market saw declines across major indices, with Oracle's stock dropping over 5%, and significant losses in other tech giants, resulting in a total market value loss of $164.8 billion [1] Group 2 - The Nasdaq China Golden Dragon Index fell by 0.73%, with most popular Chinese stocks declining, including Pinduoduo and NIO, while Baidu saw a slight increase [2] - WTI crude oil futures rose by $0.67 to $55.94 per barrel, and Brent crude oil futures increased by $0.76 to $59.68 per barrel, indicating a positive trend in oil prices [2] - Micron reported a 57% year-over-year increase in adjusted revenue to $13.64 billion, driven by surging demand for AI data centers and a shortage of storage chips, leading to a significant capital expenditure increase [6] Group 3 - Google launched a more efficient version of its AI model, Gemini 3 Flash, which outperforms its predecessor in benchmark tests and is significantly cheaper to operate [3] - The White House is expected to announce a drug pricing agreement with Novartis and Roche, aimed at easing trade tensions and potentially including other pharmaceutical companies [4] - AMD's CEO met with China's Minister of Industry and Information Technology to discuss cooperation in the digital economy and AI sectors, with AMD planning to deepen investments in China [5] Group 4 - OpenAI is negotiating with Amazon for at least $10 billion in funding, which could raise its valuation to over $500 billion, while exploring commercial collaborations [8] - Netflix plans to complete its acquisition of Warner Bros. Discovery within 12 to 18 months, following the rejection of a hostile takeover bid from Paramount [9] - SpaceX has informed employees of a regulatory quiet period ahead of its planned IPO in 2026, restricting discussions on the company's growth and valuation [10] Group 5 - Tencent announced a restructuring of its AI model team, appointing a former OpenAI researcher as chief AI scientist to enhance its AI development capabilities [11] - CICC plans to merge with Dongxing Securities and Xinda Securities through a share swap, which could elevate CICC's total assets to over one trillion yuan [12] - The stock of Muxi Co., known as the "second domestic GPU stock," surged on its debut, with significant profits reported for investors [13]

Core Insights - Neuralink has completed a $650 million Series E funding round, setting a new record in the brain-computer interface (BCI) sector, bringing its total funding to over $1.3 billion, which is significant compared to the global BCI market size of $2.6 billion in 2024 [1][2] - Despite substantial funding, Neuralink faces high operational costs, burning several hundred million dollars annually without a clear path to commercialization [2][3] - The BCI industry is experiencing a funding boom, with nearly 100 financing events in the past five years in China alone, totaling over 10 billion yuan, indicating strong investor interest [3][4] Funding Landscape - Neuralink's funding history includes multiple rounds, with significant contributions from major investors like ARK Invest and Sequoia Capital in the latest round [2] - The BCI sector has seen a 30% increase in financing events in China from January to November 2025, with notable records set by companies like JieTi Medical [5] - Government funding is becoming increasingly important, with various local and national policies supporting BCI development, including a 10 billion yuan fund in Tianjin [6][7] Market Dynamics - The BCI market is characterized by a lack of stable commercialization and profitability, leading many companies to face survival challenges [3][4] - Investors are shifting focus from upstream technology to practical clinical applications and commercialization capabilities, indicating a maturation of the investment landscape [6] - The potential applications of BCI technology, such as restoring vision or mobility, present significant market opportunities, attracting early investments [4] Product Development and Commercialization - Companies are adopting a "laying eggs along the way" strategy, focusing on both research and consumer applications to maintain cash flow [9][10] - Non-invasive BCIs are targeting consumer healthcare markets, while invasive BCIs are focusing on research applications due to the complexity of clinical scenarios [10][12] - Successful commercialization examples include products like the intelligent bionic hand from QiangNerve Technology, which has seen rapid sales growth [11] Future Outlook - 2025 is anticipated to be a pivotal year for the BCI industry in China, with significant clinical advancements expected [15] - Challenges remain in signal processing, material compatibility, and market education, which could delay widespread commercialization [16] - Companies must balance short-term survival with long-term innovation to thrive in the evolving BCI landscape [18][19]

Core Insights - The article discusses the competition between Sam Altman, CEO of OpenAI, and Elon Musk in the brain-computer interface (BCI) sector, highlighting the recent developments at Merge Labs, a company co-founded by Altman [1][2][5]. Company Developments - Merge Labs has recruited Mikhail Shapiro, a prominent researcher from Caltech, known for his work in non-invasive brain imaging and gene therapy [1][5][7]. - Altman is expected to serve as the chairman of Merge Labs, while Shapiro is anticipated to play a key leadership role in the company [5]. - Merge Labs is reportedly in discussions for a $250 million funding round led by OpenAI, which would value the company at $850 million [5]. Technology Approach - Merge Labs aims to develop a non-invasive brain-computer interface using "gene therapy + ultrasound" methods, contrasting with Neuralink's invasive techniques [5][11]. - Shapiro's research focuses on using ultrasound to interact with the brain without the need for surgical procedures, which is a significant departure from Neuralink's approach [7][12]. Industry Context - The article outlines the ongoing debate between invasive and non-invasive BCI technologies, with the former posing higher risks and potential complications [12]. - Altman has publicly expressed his preference for non-invasive methods, indicating a strategic direction for Merge Labs that may influence the future of human-AI integration [5][12].

Core Viewpoint - The article discusses the recent A-round financing of Zhiruan Medical, highlighting its focus on developing next-generation technologies and conducting large-scale clinical trials [3][4]. Financing and Company Background - Zhiruan Medical has completed over 300 million yuan in A-round financing, led by various investors including social security funds and venture capital firms [3]. - Since its establishment in 2022, the company has raised nearly 500 million yuan in total financing [4]. - The company was co-founded by Dr. Fang Ying and Dr. Song Qi, both of whom have extensive backgrounds in neuroscience and AI medical technology [4]. Technology and Innovation - Zhiruan Medical specializes in invasive brain-computer interface (BCI) technology, which allows for high-resolution neural signal collection and precise neuron modulation [5]. - The company has developed proprietary high-throughput flexible electrodes that have received patent authorization in both China and the U.S., enabling efficient neural signal collection [5][6]. - A fully implanted high-throughput wireless signal acquisition system has been created, capable of collecting neural action potentials from up to 1024 channels [6]. Research and Development - The company has built a high-precision brain data platform with over 20TB of animal neural data and 6TB of human deep brain data to enhance model training and decoding performance [6]. - Zhiruan Medical has also developed a multi-degree-of-freedom implantation robot to improve the efficiency and safety of electrode implantation [6]. Industry Context - The global BCI industry is entering a rapid growth phase, with companies like Neuralink making significant advancements in human clinical trials [7]. - The shift from rigid to flexible electrodes is seen as crucial for improving signal quality and reducing immune response risks, which are key factors for clinical application [7]. - Invasive BCI technology is expected to make breakthroughs in treating conditions such as spinal cord injuries, ALS, and depression [7].

Summary of the Conference Call on Botao Bio Industry Overview - **Industry**: Brain-Computer Interface (BCI) Technology - **Company**: Botao Bio - **Investment**: Acquired a 5% stake in Qingchuang Vision, a brain-computer interface company focused on depression treatment, leveraging technology from Zhejiang University [2][3] Key Points and Arguments - **Strategic Shift**: Botao Bio aims to transition from diagnostics to integrated diagnosis and treatment, particularly in the BCI sector [2][4] - **Government Support**: The Chinese government has prioritized BCI technology, allocating over 30 billion for development by 2030, with an additional 16.8 billion planned for the coming years [2][5] - **Market Potential**: The BCI technology market is vast, with over 1 billion patients suffering from major brain diseases in China, including nearly 100 million with depression [3][15] - **Technological Distinction**: BCI technology is categorized into invasive (high signal quality, up to 50 kHz) and non-invasive (lower signal quality) methods, with applications in rehabilitation and treatment of severe brain diseases [2][7][9] - **Research Landscape**: BCI research is primarily conducted in universities and research institutions, with leading companies like Zhiruan and Xingdao at the forefront [10] Additional Important Content - **Clinical Applications**: Current applications of BCI technology include rehabilitation for motor functions and sensory restoration, with significant room for growth in treating major brain diseases [9][15] - **Challenges in Development**: Invasive BCI technology faces high barriers due to its interdisciplinary nature, requiring collaboration across fields such as computer science, materials science, and clinical medicine [13] - **Unique Technologies**: Botao Bio has developed three core technologies for depression treatment, focusing on precise implantation, real-time emotional state monitoring, and closed-loop stimulation adjustment [19] - **Collaborations**: The company has established partnerships with Zhejiang University’s affiliated hospitals for clinical trials and research [21] - **Future Directions**: Plans for product development include a second-generation device with self-developed chips, aiming for clinical trials and eventual market release by 2029 [24][28] Market Dynamics - **DBS System Comparison**: Botao Bio's deep brain stimulation (DBS) system is designed to record, stimulate, and compute, differentiating it from existing products in the market [27] - **Patient Acceptance**: There is a high demand for new therapies among treatment-resistant depression patients, indicating a favorable market environment for innovative solutions [29] - **Regulatory Landscape**: The company anticipates regulatory approval for its DBS system by 2029, with a focus on personalized treatment approaches [28] Conclusion - **Investment Opportunity**: The BCI sector, particularly in depression treatment, presents significant investment potential driven by government support, technological advancements, and a large patient population in need of innovative therapies [2][5][15]

Group 1 - The State Council emphasized the need to promote the construction of "good houses" and integrate it into urban renewal mechanisms, providing policy support in planning, land, finance, and other areas to stabilize the real estate market [4][5] - The People's Bank of China announced a 400 billion yuan reverse repurchase operation to maintain liquidity in the banking system, with a term of 182 days [4] - The CSRC released new regulations for algorithmic trading in the futures market to enhance monitoring and risk management [4] Group 2 - The National Development and Reform Commission allocated 80 billion yuan for urban renewal projects, benefiting approximately 1.7 million people [5] - A series of adjustments to A-share indices took effect on June 16, including major indices like the Shanghai Composite and Shenzhen Component [5][6] - Shenzhen is expected to pilot a secondary listing for red-chip stocks, providing a more efficient listing channel for tech companies [6] Group 3 - Global markets experienced significant volatility on June 13 due to escalating geopolitical tensions in the Middle East, with major indices in the US and Europe declining [7] - The Israeli airstrikes have resulted in significant casualties in Iran, further heightening regional tensions [7] Group 4 - GAC Group committed to ensuring the completion of dealer rebates within two months [10] - Kweichow Moutai adjusted its 2024 profit distribution plan, increasing the dividend to 27.673 yuan per share [10] - *ST Guandao faces potential delisting due to financial fraud, with trading suspended for one day [10] Group 5 - Huatai Securities reported that the conflict between Israel and Iran has led to increased oil price volatility [14] - CITIC Securities noted that new models of real estate development will more effectively address structural supply-demand mismatches [15] - The computer industry is expected to maintain a positive trend, with a focus on AI applications and smart vehicles [17]

Group 1: Earth Physics Satellite Launch - The first Earth physics field detection satellite, "Zhangheng-1" No. 02, was successfully launched using the Long March 2D rocket from the Jiuquan Satellite Launch Center [1][3] - This satellite is a significant achievement in the construction of detection capabilities in the field of Earth physics, enhancing China's "sky-space-ground" monitoring capabilities for major natural disasters [3][5] - It carries nine scientific detection devices, including an electric field detector, for real-time monitoring of global electromagnetic fields, electromagnetic waves, ionosphere, and neutral atmosphere parameters [5] Group 2: Invasive Brain-Computer Interface Clinical Trial - China has successfully conducted its first prospective clinical trial of an invasive brain-computer interface, in collaboration with the Fudan University Huashan Hospital and related enterprises [5][7] - This achievement positions China as the second country globally to enter the clinical trial phase for invasive brain-computer interface technology [7] - The system aims to improve the quality of life for patients with spinal cord injuries and amputations through motor function replacement technology [7] Group 3: Yellow River Railway Steel Arch Bridge - The first railway steel arch bridge crossing the Yellow River, the Qinhai Jianza Yellow River Super Bridge, has entered the main bridge closure phase [7][10] - The completed suspension tower weighs 1,800 tons, with a maximum cable force of 1,161 tons [10][12] - The bridge is expected to achieve closure by August 2023 [10] Group 4: Yttrium-90 Production Breakthrough - China has successfully mastered the commercial production technology of Yttrium-90, with the first batch of Yttrium-90 glass microspheres produced and passing relevant tests [12][14] - The Qinshan Nuclear Power Base's commercial heavy water reactor has unique advantages for Yttrium-90 production [14] - Yttrium-90 glass microspheres are radioactive isotopes used for precise treatment of liver tumors through vascular intervention [12][14]